Q1 FY26: Revenue up by 2.1% Y-o-Y and EBITDA margin at 24.1%

RPG Life Sciences Limited has announced its financial results for the first quarter ended June 30, 2025.

In Q1 FY26, RPG Lifesciences revenue recorded 2.1% Y-o-Y increase in sales (18.1% Q-o-Q growth) along with a healthy EBITDA margin of 24.1%. Profit before tax remained largely in line with previous year.

Commenting on the results as well as the outlook of the business, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd. said, “In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.”

“We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders,” added Nair.

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India’s fastest-growing business groups with a turnover of US$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.